Avidity Biosciences (RNA) Operating Income (2019 - 2025)
Historic Operating Income for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$188.8 million.
- Avidity Biosciences' Operating Income fell 9239.61% to -$188.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$612.5 million, marking a year-over-year decrease of 8862.76%. This contributed to the annual value of -$378.9 million for FY2024, which is 6084.01% down from last year.
- Per Avidity Biosciences' latest filing, its Operating Income stood at -$188.8 million for Q3 2025, which was down 9239.61% from -$171.1 million recorded in Q2 2025.
- Avidity Biosciences' 5-year Operating Income high stood at -$23.9 million for Q1 2021, and its period low was -$188.8 million during Q3 2025.
- Moreover, its 5-year median value for Operating Income was -$57.6 million (2023), whereas its average is -$73.8 million.
- In the last 5 years, Avidity Biosciences' Operating Income plummeted by 28791.87% in 2021 and then plummeted by 1368.28% in 2023.
- Quarter analysis of 5 years shows Avidity Biosciences' Operating Income stood at -$38.5 million in 2021, then crashed by 38.08% to -$53.2 million in 2022, then dropped by 25.4% to -$66.7 million in 2023, then plummeted by 81.28% to -$121.0 million in 2024, then plummeted by 56.05% to -$188.8 million in 2025.
- Its last three reported values are -$188.8 million in Q3 2025, -$171.1 million for Q2 2025, and -$131.5 million during Q1 2025.